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T lymphocytes play an important role in the patho- genesis of psoriasis; however, the main topic of debate today is whether T lymphocytes may be 
considered as the initiators of psoriasis or as the main- 
tainers of a “psoriatic milieu” responsible for the charac- 
teristic dermal and epidermal alterations in psoriasis. Ac- 
cording to the latter point of view, T lymphocytes are 
recruited to the skin and activated nonspeci6cally via 
chemokines, followed by adherence to upregulated ad- 
hesion molecules on endothelial cells in lesional skin. We 
reviewed the literature on T lymphocytes in psoriasis and 
attempted to delineate their role in the pathogenesis of 
psoriasis. 
T-Cell Idltrates in Different Stages of 
the Disease 
Uninvolved Psoriatic Skin 
Some decades ago it was stated that “psoriasis exists as a 
basic aberration throughout the skin” and that “clinically 
uninvolved skin of psoriatic patients is not normal.“’ 
These statements are still valid today, even when im- 
munophenotypic and polymerase chain reaction (PCR) 
studies on T-lymphocyte subsets in uninvolved psoriatic 
skin are considered.2” Besides epidermal alterations such 
as enhanced proliferation and biochemical, enzymatic, 
and cytokine abnormalities, uninvolved psoriatic skin is 
further characterized by dilated capillaries and a variable 
degree of perivascular, perifollicular, and epidermal lym- 
phocytic infiltration. 4$ The different immunoregulatory 
T-lymphocyte subsets are equally represented, but the 
absolute numbers of CD4+ and CDS+ T lymphocytes are 
significantly increased. 4*5 Such alterations are generally 
not observed in the skin of healthy individuals. Histolog- 
ically, with respect to the numbers and distribution of T 
lymphocytes, uninvolved psoriatic skin seems to form an 
intermediate between normal healthy skin and lesional 
psoriatic skin. Uninvolved skin of psoriatic patients also 
contains small numbers of the HLA-DR+/CDla- sub- 
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class of antigen-presenting cells (APCs), which have an 
enhanced capacity to stimulate T cells.**7 Together with 
local T lymphocytes, these APCs may be involved in the 
initiation of psoriasis. All alterations in uninvolved skin 
mentioned above, referred to as pr@psor&ds, make it un- 
derstandable as to why the whole skin of gene&ally pre- 
disposed individuals can develop psoriasis. 
Early Psoriatic Macule or Pap& 
Extravasation of CD4+ T lymphocytes and monocytes is 
the earliest immunohistologie altomtion in newly arising 
psoriatic lesions.5 Some studies indicate that degranula- 
tion of resident dermal mast cells maybe a m event. 
Mast cell products initially induce en&h&al cell gaps 
and activation, perforation of the basement membrane, 
and the subsequent extravasation of mononuclear cells 
followed by epidermal changes.* T lymphocytes and 
monocytes are first seen perivascularly, mainly in the 
papillary tips? Monocytes &grab toward ,&he basement 
membrane and remain there lined up in close pr&mity to 
epidermal basal cells.‘* T 1 
and invade the epidermis 
(Plate 6). At this stage, 
trophils are scarce. w* The contrihtions of CD4f and 
CDB+ T lymphocytes are equal, with a CD4KD8 ratio of 
approximately 1. 4,5 A further increase in this ratio is ob- 
served in cases of rapid evolution in lesions. 
Based on the observation that,the extr nd sub- 
sequent infiltration of CD4+/CD25+ T lymphocytes into 
the epidermis precede the epidermal &an-, some au- 
thors suggest that T lymphocytes and monocytes play a 
key role in the induction of new psoriati lesiorts.f3 Rde- 
vant to the early involvement of T lymphocytes is the 
marked increase in the number of HLA-DR+/CDla- 
dendritic cells and the slight decrease in the number of 
HLA-DR+/CDla+ Langerhans cells in the epidermis 
from early psoriatic skin lesions.5#6 In a&&m, intraepi- 
dermal CD4+ T lymphocytes were observed in close ap- 
position to HLA-DR+ dendritic cells, a picttrre normally 
seen in contact hypersensitivity skin reactional4 
Guttate Psoriatic Lesion 
In the guttate lesion there are sufficient changes that 
make the histologic diagnosis of psoria& pocks&k. The 
infiltrate is more pronounced, there is still a predomi- 
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nance of T lymphocytes, and monocytes and neutrophils 
are now well represented in the infiltrate.15 Neutrophils 
are also seen in the epidermis, especially at sites with 
evident parakeratosis.16 
The association between guttate psoriasis and group A 
/?-hemolytic streptococcal infection is well documented.” 
Generally, the course of events induced by triggering fac- 
tors resulting in typical psoriatic lesions remains largely 
unclear. The poststreptococcal or guttate psoriasis model 
is an attractive one because of the involvement of a clear 
antigen. In the latter model, reactivity of antibodies or 
T-cell receptors (TcRs) to streptococcal antigens, espe- 
cially M protein, which shares homology with human 
keratin, is considered to be a conceivable mechanism.*8Jg 
This cross-reactive immune response induces local acti- 
vation of the skin immune system and, finally, psoriatic 
lesions in individuals with the “psoriatic genotype.” A 
similar mechanism may also occur in acute rheumatic 
fever.*O The following observations provide evidence for 
the induction of guttate psoriasis by group A P-hemo- 
lytical streptococci: (1) antibodies to streptococcal M pro- 
teins cross-reacted with normal and lesional psoriatic 
skinzl; (2) streptococcal antigens induced enhanced pro- 
liferation of T lymphocytes from the peripheral blood and 
skin lesions of patients with guttate and plaque-type le- 
sions18,22; (3) these T cells were of the CD4+, TcR a//?-l-, 
and memory phenotype and produced helper-T-cell type 
1 cytokines such as interleukin-2 (IL2) and interferon y 
(IFN-Y)~*,~~; (4) local administration of streptococcal anti- 
gen induced new psoriatic lesions24; and (5) there is a shift 
of peripheral T cells, similar to streptococcal antigen-spe- 
cific T cells, expressing TcR p chain variable (V) gene 
segment 2 (VP) to dermis and epidermis and, to a lesser 
extent, of V/35.1+ T cells to dermis in patients with guttate 
and plaque-type psoriasis.23,z5 
Pustular Lesion 
Immunohistologic time course studies on pustular psori- 
asis are scarce, but some studies on palmoplantar pustu- 
losis are available. Polymorphonuclear neutrophils are 
the most prominent cells in this form of psoriasis. In the 
earliest phases, however, neutrophil accumulation is pre- 
ceded by T-cell infiltration into the epidermis.26,27 As in 
early nonpustular psoriatic lesions, the epidermal T lym- 
phocytes are CD4+/CD25+ and are seen in close appo- 
sition to epidermal dendrocytes.” Marked attraction of 
neutrophils forming Munro’s microabscesses or spongi- 
form pustules of Kogoj also occurs in plaque-type lesions 
and has been related to increased local production of 
IL-8.2**29 The latter assumption is questionable because 
IL-8 is also overexpressed in other cutaneous disorders 
such as allergic contact dermatitis, lichen planus, and 
mycosis fungoides (own immunohistochemical observa- 
tions) in which neutrophils are not prominent or even 
absent. In all likelihood, a combination of the altered 
interactions with the psoriatic endothelium and the epi- 
dermis and the spectrum of locally produced chemoat- 
tractants underlies this specific pattern of neutrophil at- 
traction. It may well be that in pustular psoriasis there is 
further aberration of the altered epidermal cytokine pro- 
file. To date, the exact basis for the specific attraction of 
neutrophils remains unclear. 
Plaque-Type Lesion 
In plaque-type lesions the dense inflammatory infiltrate 
in the dermis is composed of lymphocytes, monocytes, 
dendrocytes, and polymorphonuclear leukocytes. In the 
dermis, T lymphocytes are seen perivascularly and at the 
tips of the elongated papillae. Activated T lymphocytes 
are regularly observed in the epidermis. The number of 
intraepidermal T lymphocytes is highest in psoriasis 
when compared with other inflammatory skin diseases. 
Studies by different authors have demonstrated that the 
epidermal T lymphocytes are of the helper-inducer or 
memory type and express the following membrane 
markers: CD4, CDlla, CD25, CD45R0, CD49d, CD54, 
Cdw60, HLA-DR, CLA (Plate 7)?*4,6J1,30-323 
Based on their cytokine production profile, human 
CD45RO+ helper T lymphocytes may be classified into 
helper T type 0, 1, and 2 lymphocytes (Mossman T. Oral 
communication, Third International Conference on Cy- 
tokines, March 28-30, 1994). It was unclear whether in 
psoriasis the infiltrating lymphocytes belonged to the 
helper T type 1 or helper T type 2 (IL-4 and IL-5 produc- 
ers) subset because little was known about the profile of 
cytokines produced by T lymphocytes in situ in psoriatic 
lesions. Elevated levels of IL-2, soluble IL-2 receptor, 
IFN-y, and IFN-y-induced protein-10 (y-IP-10) have been 
reported in psoriatic lesions, whereas IL-4 was never 
detected.33-35 Thus, these data favor a role for helper T 
type 1 lymphocytes in the pathophysiology of psoriasis. 
This was recently corroborated’by the results of PCR ex- 
periments by Uyemura and others for the detection of 
cytokine mRNA in skin extracts from lesional and nonle- 
sional psoriatic skin and healthy control skin3 
Signs of T-Ceil Activation in Psoriasis 
Further indirect evidence for the involvement of the cel- 
lular immune system has been obtained from blood, 
serum, suction-blister fluid, and urine and skin tests of 
psoriatic patients. Peripheral blood of psoriatic patients 
displays signs of T-cell activation such as an increased 
number of activated (CD25+/HLA-DR+) T lymphocytes 
(Table 1)6 and elevated levels of soluble IL-2 receptor, 
soluble CDS, and soluble intercelIular adhesion molecule 
1 (ICAM-1) and shows increased migratory activity in 
response to appropriate chemoattractants.a6-4s These 
findings merely represent markers for inflammation and 
are not specific for psoriasis, because elevated levels of 
serum IL-2 receptor are also observedin atopic dermatitis, 
rheumatoid arthritis, and other inflammatory diseases.3’ 
Suction-blister fluid from psoriatic plaques contains ele- 
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Table 1. lmmunophenotyping of Peripheral Blood Mononuclear 
Cell Samples From Patients With Psoriasis, Control Subjects, and 
Patients With AIIewic Contact Dermatitis @CD) 
Patients Patients 
With Controls With 
Monoclonal Psoriasis Subjects ACD 
Antibody (n = 24) (n-60) (n = 24) 
CD20 6.1 t 2.5 7.0 f 3.7 6.2 f 3.6 
CD3 57.7 +- 8.2 59.1 rf: 13.1 61.1 f 9.6 
CD4 38.2 f 6.6 38.4 2~ 10.9 38.1 f 9.5 
CD8 20.5 4 6.3 20.8 -+ 5.4 23.1 f 5.4 
CD4/CD8 2.0 k 0.9 2.0 -+ 0.8 1.7 zk 0.8 
CD14 22.6 zk 8.6 18.9 t 8.5 19.1 + 7.7 
HLA-DR 29.3 + 8.3 27.5 k 8.8 27.6 If: 8.1 
CD25(IL-2 receptor) 4.4 2 9.7” 0.2 zk 0.2 1.1 f 0.6 
CD7lWW 4.3 I!z 4.8* 0.5 2 0.5 1.7 + 1.2 
Note. Results are eqmwed as the mean percentage f SD of monocyte and lympho- 
cyte subsets in PfMC samples from patients with psoriasis, healthy control subjects, 
and patients with AW. clusters ofdiferentiation (W) am shown. 
* P < .oOl, WT, tohm compared with the results for healthy control subjects. 
t 273, transferh receptor. 
vated IL-6, IFN-y, and IFN-cu activity.33~~~41 Psoriatic pa- 
tients with increased IL-6 levels in blister fluid from 
plaque-type lesions displayed no increase in IL-6 levels in 
blister fluid from nonlesional skin and in serum.*’ This 
indicates that the IL-6 was locally produced in the psori- 
atic lesions; however, other studies of patients with se- 
vere psoriasis did show elevated serum levels of IL-6 
possibly derived from activated peripheral blood mono- 
nuclear cells (PBMCS).~,*~ Levels of IFN-y and IFN-(w are 
also increased in the sera from psoriatic patients and cor- 
relate positively with disease activity.” Immunohistolo- 
gically, the expression of IFN-a and IFN-y was confined 
to basal keratinocytes and to stratum corneum and der- 
ma1 mononuclear cells, respectively.& Lesional T lym- 
phocytes are to be considered the most likely source of the 
elevated IFN-7 levels because keratinocytes do not pro- 
duce bioactive IFN-Y.*~ Indeed, in vivo, psoriatic kerati- 
nocytes exhibit signs of exposure to IFN-7 such as expres- 
sion of y-IP-10 and ICAM-1, but in most cases not 
HLA-DR.=*’ The expression of these molecules partially 
parallels the elevated levels of IFN-7 in psoriatic lesions. 
The sporadic expression of HLA-DR on psoriatic kerati- 
nocytes is remarkable and probably based on the differ- 
ences in responsiveness to IFN-y between normal and 
psoriatic keratinocytes. 48-5o Psoriatic keratinocytes show 
decreased upregulation of HLA-DR, less inhibition of cell 
growth, enhanced production of transforming growth 
factor (TGF-ar), and no downmodulation of their epider- 
mal growth factor (EGF)/TGF-a! receptor on stimulation 
with IFN-y. 49,ao In psoriatic skin the IFN-y receptors are in 
fact confined to the basal epidermal layers, whereas the 
IFN-y receptors are distributed throughout the epidermis 
of normal skins1 The reported induction or exacerbation 
of psoriasis by recombinant IFN-1/ and IFN-a stresses 
their inductive role in this disease.52s53 
The urine of psoriatic patients contains increased 
levels of neopterin, a substance indirectly related to T-cell 
activation.54S5 The concentration of neopterin in the 
urine seems to correlate positiveiy with the disease activ- 
ity in psoriasis, whereas different ant@soriatic treatments 
significantly reduce the level of neopterin in the urine.935 
In vivo delayed hypersensitivity skin test reactions to 
dinitrochlorobenzene (DNCB), a potent sensitizer, seem 
to be impaired in psoriatic patients.% The impairment 
appears to be related to the disease activity, because pa- 
tients free of lesions do not exhibit this impairment. In- 
tradermal tests using purified mycobacterial protein 
derivative (PPD) and streptokinase/st@dornase par- 
tially contirmed the results obtained with DNCB, because 
48 hours after skin testing, only the skin reactions to 
streptokinase/streptodornase differed significantly from 
those of the controls.56 In the same study, it was noted 
that the reactions to PPD persisted longer in patients with 
psoriasis, which suggested an impaired ability to switch 
off cell-mediated immune reactions. 
Evidence for Immunopathogenic Mechanisms 
in Psoriasis 
The potential pathogenic role of bone marrow-derived 
cells in psoriasis is illustrated by the clearance of long- 
standing severe psoriasis after allogeneic bone marrow 
transplantation5’ as well as induction of psoriasis in a 
recipient of I-ILA-matched bone marrow from an individ- 
ual with psoriasis. 58 Moreover, manifestation of psoriasis 
in a patient without neutrophils and monocytes in the 
peripheral circulation again indicates a prominent role for 
T lymphocytes in the initiation of psoriasi~~ This case 
also indicates that neutrophils are not a prerequisite for 
the initiation of psoriasis. Studies on intravenous admin- 
istration of anti-CDS/CD4 rnonoclmal antibodies 
showed that depletion of circulating T IymPhocytes re- 
sulted in the improvement of psoria~is.~ Finally, the 
course of psoriasis is generaIly characterized by remis- 
sions and exacerbations of the disease. A similar course is 
also often observed in classic autoimmune (skin)diseases. 
In the latter case, the variation in disease activity is athib- 
uted to the imbalances between effector and suppressor 
mechanisms of the immune ~ystem.~l Comparable mech- 
anisms may regulate disease activity in psoriasis. In con- 
clusion, these observations indicate that the abnormali- 
ties in psoriatic keratinocytes may be tr@ped by, or are 
highly dependent on, CD4+ T lymphocytes and their 
cytokines and emphasize the importance of immuno- 
pathogenic mechanisms in psoriasis.62,63 
In Vitro Studies on the Fun&m of T 
Lymphocytes in Psoriasis 
Data on the in vivo situation showing that T lymphocytes 
are consistently involved in early psoriatic lesions were 
summarized in the previous paragraphs. These data sup- 
port the hypothesis that psoriasis is a disease of keratino- 
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cyte proliferation induced by T lymphocytes and T cell- 
derived proinflammatory agents.13 The most relevant 
data on in vitro T lymphocyte function in psoriasis are 
presented in the following paragraphs. 
Cell-Mediated Zmmunity 
The data on cell-mediated immunity in psoriasis are con- 
flicting. Early studies reported a decreased proliferative 
response of PBMCs from psoriatic patients after stimula- 
tion with mitogens such as phytohemagglutinin (PHA) 
and concanavalin A (ConA)64,65; however, normal re- 
sponses to PHA and pokeweed mitogen have also been 
reported. 66 CD3-triggered peripheral T-cell proliferation 
is decreased, but is enhanced by extracellular matrix 
(ECM) components. 67 The autologous mixed-lymphocyte 
reaction (MLR) appears to be decreased in patients with 
psoriasis, with the proliferation inversely correlated with 
disease activity. 68 The decreased proliferation was attrib- 
uted to the reduced production of IL-2 and IFN-7 by 
peripheral blood T lymphocytes69; however, this de- 
creased response to stimuli of psoriatic T cells was not 
observed in vitro in our studies.6 As mentioned, in other 
articles consistently increased levels of IFN-y and IL-2 
receptor in suction-blister fluids and sera from psoriatic 
patients were reported. 33*37,44 These inconsistent findings 
may be related to arbitrary conditions, such as timing of 
the in vitro testing in relation to disease activity. In vitro 
testing for drug allergy, for example, has shown that a 
severe drug eruption is followed by a period of “anergy” 
during which PBMCs show decreased or no antigen-spe- 
cific proliferation. Restoration of antigen-specific prolif- 
eration in PBMCs depends on clearance of the drug erup- 
tion and is usually observed some weeks later.‘O 
T cells from peripheral blood of psoriatic patients, in 
the absence of added antigen, show a clear proliferative 
response in viko to autologous epidermal cells from le- 
sional as well as uninvolved skin.6,71,72 Such a reaction is 
called the autologous mixed epidermal cell-T lympho- 
cyte reaction (MECLR). Increased autologous MECLR is 
also observed in cutaneous T-cell lymphoma and atopic 
dermatitis and after 4 MED UVB irradiation of normal 
~kin.~~-~ In cutaneous T-cell lymphoma and atopic der- 
matitis, the autologous MECLR is increased only when 
epidermal cells from involved skin are used.73,74 
Putative Psoriasis-Related Antigen 
At present, it remains unclear whether the MECLR is 
antigen driven. Nevertheless, the epidermal HLA-DR+ 
APCs play a central role by presenting antigen (putative 
psoriasis-related) to autologous T lymphocytes.6,76 Skin- 
infiltrating T cells in psoriasis may recognize MHC class 
II-associated molecules like superantigens or autopep- 
tides present in the MHC groove.m’s As discussed earlier, 
M proteins of group A /3-hemolytic streptococci or myco- 
bacterial peptides may act as superantigens via molecular 
mirni~ry.‘~ Other potential antigens may be persisting 
viral or rekoviral antigens, drugs themselves, or drug-in- 
duced MHC class II-associated neoepithelial anti- 
gens.‘6J9,*0 In fact, alterations in (the glycosylation of) 
plasma membrane proteins are primary features of the 
psoriatic keratinocyte. 81 Although clear evidence has to 
be provided, these neo-epithelial proteins may be recog- 
nized as nonself on recognition by immunoregulatory 
cells. Examples of these upregulated (keratinocyte-spe- 
cific) proteins include calgranulins A and B, carcinoem- 
bryonic antigen, cystatin A, psoriasin, Pso 27, and psoria- 
sis-associated fatty acid-binding protein (PA-FABP).s2-” 
This altered protein expression seems to be related to the 
hyperproliferative state of these cells, inflammatory 
stimuli or both.82 Other “aberrant” membrane markers 
expressed by psoriatic keratinocytes are squamous cell 
carcinoma-related antigen, CD13, CD14, CD36, and 
CD68.85-87 Despite the data in favor of an epidermal pso- 
riasis antigen, such an antigen may not be solely confined 
to the skin. This may explain the occurrence of arthritis in 
a proportion of the patients. 
Accessory Cells 
Analysis of the APC function in the MECLR shows that 
not the “classic” Langerhans cells (LCs) (HLA-DR+/ 
CDlai-), but HLA-DR+/CDla- APCs are the principal 
stimulators of T cells in this reaction (Fig 1).6 Lesional 
keratinocytes do not stimulate T cells in the MECLR, 
probably as result of the limited number of HLA-DR+ 
keratinocytes in psoriatic lesions.ss Our own findings in- 
dicate that, besides HLA-DR, adhesion molecules such as 
CD2, CDlla, CD18, CD54, CD58, and membrane-asso- 
ciated IL-l on psoriatic epidermal cells also fulfill an ac- 
cessory role in the autologous MECLR (Prens E. Submit- 
ted for publication). In normal skin, only one type of 
epidermal APC -the HLA-DR+, CDla+, Fc-y and Cs 
receptor-bearing LC - predominates.@‘“0 This means 
that epidermal cell suspensions depleted of HI.&DR-t/ 
CDlai- LC are unable to present antigen to autologous T 
cells to stimulate allogeneic T cells.91*g2 
Several reports describe the predominance of HLA- 
DR+ cells over CD1 a+ cells in epidermal cell suspensions 
from psoriatic lesions (Table 2).6,93,94 It is known that cul- 
tured LCs lose their CDla expression and cytoplasmic 
Birbeck granules, but the expression of HLA-DR is upreg- 
ulated and their stimulator-y capacity is increased.95-97 
Fresh LCs process and present native antigen more effi- 
ciently than cultured LCs, whereas cultured LCs are 
equally efficient at presenting preprocessed antigen, but 
superior at stimulating allogeneic T lymphocytesP6”7 
Cultured LCs exhibit a unique feature that is not shared 
by fresh LCs, namely, an extraordinary capacity to stimu- 
late syngeneic T lymphocytes.97 Thus, fresh and cultured 
LCs may be considered as the in vitro representatives of 
their in vivo counterparts, respectively: inkaepidermal 
LCs and LCs that have migrated to the draining lymph 
nodes (nodal LCS).~’ Elevated levels of cytokines may 
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untreated CDla depleted HLA-DR depleted HLA-DR blocked 
Figure 1. The role of HLA-DR+ and HLA-DR/CDla-f- skin AK subsets in the 
autologous MECLR Pu@ed T lymphocytes were cocultured with autologous total 
epidermal cells (EC& CDla depleted ECs, or EC suspensions depleted of CDla+ and 
HL4-DR+ cells, all at a concentration of 4 X 1fY ECs per well. The cultures were 
pulsed with tritiafed fhymidine and harvesfed 8 hours lafer. Blocking was petformed by 
addition of dialyzed anti-HlA-DR mAb to the cultures. Filled, bold speckled, fine 
speckled, and blank bars represent he an’thmetic mean rt SEM dpm of quadruplicate 
cultures on the day of maximum proliferation of an individual patient. Paired results of 
four representative patients are shown. Reprinted with permission from Frens et al6 
alter the microenvironment in psoriatic lesions in such a 
way that in vivo lymph node or in vitro culture conditions 
are stimulated. As the phenotype and some functional 
characteristics between “cultured’ LCs and HLA-DR+/ 
CDla- APCs occurring in psoriatic lesions are similar, 
the latter cell type may be considered as the in vivo 
equivalent of in vitro “cultured” LCS.~* Thus, HLA- 
DR+/CDla- APCs in psoriatic lesions probably repre- 
sent cytokine-activated LCs. 
Interference of T Lymphocytes With Stroma and 
Epidermal Cell Behavior 
Extravasation, (epi)dermal recruitment, and recirculation 
of T lymphocytes are essential processes for immune sur- 
veillance of the shin. Lymphocyte trafficking comprises at 
Table 2. Levels of Expression of Activation Markers on Epidenal 
Cells From Lesionnl Psoriatic 0 Uninvolved Psoriatic OW, 
and Healthy Control RIN) Skin 
Percentage Expression 
Marker PP PN NN 
CD36(OKM5)f 23 -t 12’ 0.3 -+ 0.1 0.5 zk 0.1 
CDSI(ICAM-l)+ 31 rt 14’ 0.6 * 0.1 0.5 + 0.1 
mlL-1+ 57 + 21* 12 + 3’ 4 & 0.5 
HLA-DR+ 5.1 + 1.6% 1.9 + 0.6 1.6 -+ 0.4 
CDla+ 1.8 -t 0.7 1.6 zk 0.4 1.5 + 0.4 
Note. Rcsdts arc eqwessed as the mean percentage ofpositiue cells * SD. 
l These fipres are sfgnificantly higher than those for uninnobed psoriatic skin 
and/or control epidermaf ceUs. 
least two components: adhesion and migration. Celhdar 
adhesion is controlled by interactions between lympho- 
cytes and endothelial cells via adhesion molecules. Che- 
mokines, chemoattractants for leukocytes, are responsi- 
ble for the migration of lympIwcy@s to sites of 
inflammation. During cutaneous inffanmarion, adher- 
ence of T lymphocytes to the end&helium is foilowed by 
diapedesis and immigration into dermis and, k~Uy, epi- 
dermis. The interactions of T lymphocytes ti& (&p)der- 
ma1 cells and ECM components, the consequences of 
these interactions, and their role in the pathogenesis of 
psoriasis follow. 
Interaction of T Lymphocytes With Endothelinl Cells 
Adhesion of T lymphocytes to vascular endothehum in- 
volves a multistep cascade: (1) Thai “m&g” of T lym- 
phocytes on the endothelium via selectin-mediated inter- 
actions; (2) activation of T-cell integrins by chem&nes or 
divalent cations, resulting in high-affinity &and binding 
and (3) strong adhesion mediated by T-ceJI integrh~.~ 
Chemokines immobilized by en&h&al 
may regulate the type of infiltrating T 
ple of such a cytokine is macropharge 
tein (MIP)lfi. This protein preferen#ia 
cells and potentiates the adhesion of CDS-I- T cells to 
vascular cell adhesion molecule (YCAM) 
cells.l”“ Selective recruitment of T-cell 
into the skin is also evidenced by the interaction between 
cutaneous lymphocyte-associated antigen (CLA) and E- 
selectin on endothelial cells. This interaction induces di- 
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rectional migration of a unique subset of skin-associated 
memory T cells to sites of chronic cutaneous inflamma- 
tion.31J01 Once in the skin, the expression of CLA may be 
upregulated further by transforming growth factor /31 
(TGF-j.?l) and, to a lesser extent, by IL-6, both of which 
are produced by activated keratinocytes. 
Interferon y derived from infiltrating T cells regulates 
the expression of E-selectin and production of IL-6 by 
endothelial cells.102 Vice versa, endothelial cells treated 
with IFN-y were able to induce antigen-dependent pro- 
liferation and cytokine production of helper T type 2 cells, 
but not helper T type 1 cells. This implies that endothelial 
cells, by virtue of their capacity to function as accessory 
and/or antigen-presenting cells, selectively stimulate the 
transmigration and function of T-cell subsets.103 
Peripheral T cells from psoriatic patients display aug- 
mented binding to normal endothelium as compared 
with healthy controls and patients with atopic dermatitis 
and rheumatic arthritis.32J~ This augmented lymphocyte 
binding is reversible with treatment and clinical improve- 
ment. The reverse is also true. Normal CD4+ T cells bind 
specifically to dermal capillary endothelia in psoriatic 
plaques, but not in uninvolved psoriatic or normal control 
skin32 Dermal capillaries in psoriatic skin express ele- 
vated levels of ICAM-I and E-selectin, and preferentially 
allow the adherence of LFA-1+ and CLA+ memory T 
helper cells as compared with the vessels in normal skin.32 
Furthermore, in psoriasis, VCAM-1 and endoglin, a new 
180-kDa dermal endothelial celI activation antigen, are 
variably upregulated on dermal endothelium.105~106 The 
activated status of endothelium in psoriasis is further il- 
lustrated by the increased expression of (tumor necrosis 
factor a) TNF-(r and TNF receptor on dermal blood ves- 
sels.107 Cytokines such as IL-l, IL-6, TNF-ar, and IFN-y 
which predominate in the psoriatic (epi)dermal microen- 
vironment are the potential candidates for the upregula- 
tion of adhesion molecules. These molecules on psoriatic 
endothelium have been shown to be less sensitive to the 
downregulatory effects of TGF-fll .lo8 Psoriatic endothe- 
lial cells display structural abnormalities that together 
with an increased adhesiveness for T lymphocytes facili- 
tate trafficking of these cells. 
Interaction of T Lymphocytes With Fibroblasts and 
Extracellular Matrix Components 
After extravasation, skin-infiltrating T cells encounter 
dermal constituents like fibroblasts and ECM compo- 
nents. T cell- fibroblast interaction resuhs in a mutual 
activation and in an increased production of TNF-cr, IFN- 
7, and IL-6, with T cell-derived TNF-a being responsible 
for the upregulation of ICAM- on fibroblasts.lOg Thus, T 
cells initiate a cell contact-mediated mechanism for selec- 
tion, accumulation, and retention of mononuclear cells 
via fibroblast ICAM- during cutaneous inflammation.110 
Interaction of lymphocytes with ECM proteins may 
induce persistent cytokine or chemokine synthesis and 
ECM components are able to maintain tissue inflamma- 
tion in such a manner. For instance, thrombospondin, a 
protein that is highly upregulated in inflamed skin, pref- 
erentially binds to activated very late activation antigen 4 
(VLA-4) and VLA-5 present on memory T cells.111 The/31 
integrin (CD29)-mediated interaction between primed T 
cells and laminin has been shown to induce persistent 
cytokine gene expression in mononuclear cells.l12 The 
decreased CD3-triggered T-cell proliferation in patients 
with psoriasis is enhanced by collagen types I and IV and 
fibronectin.67 
The involvement of fibroblasts in the pathogenesis of 
psoriasis remains controversial. Psoriatic fibroblasts have 
been shown to induce hyperproliferation of normal kera- 
tinocytes in a skin-equivalent model.*13 Our own studies 
indicate that cultured psoriatic fibroblasts produce in- 
creased amounts of biologically active IL-6, a cytokine 
able to induce keratinocyte and lymphocyte proliferation 
(Debets R, et al. Manuscript in preparation). This altered 
IL-6 production by lesional psoriatic fibroblasts is asso- 
ciated with a decreased expression of TNF receptor and 
an altered expression of platelet-derived growth factor 
(PDGF) receptor B. lr4 At present, it is not known whether 
these alterations are of a primary nature or are merely a 
consequence of cellular activation due to T cell- 
fibroblast interactions. Thus, ECM proteins may be in- 
volved in the maintenance of psoriatic lesions. 
Interaction of T Lymphocytes With Kerutinocyfes 
Different studies on the interaction between T cells and 
keratinocytes indicate that three interactive mechanisms 
are involved: (1) via soluble cell products (cytokines), (2) 
via cell-cell contact (direct activation), (3) a combination 
of both mechanisms. Interactive signaling, autocrine, 
paracrine, and pleiotropic effects are the hallmarks of 
these mechanisms. The interaction between T cells and 
keratinocytes can affect the phenotype and function(s) of 
both cell types. Illustrative are the observations that, on 
the one hand, T cells from lesional psoriatic skin release 
growth factors that induce activation, proliferation, and a 
“psoriatic phenotype” in cultured keratinocytes.30J1s On 
the other hand, cytokines released by lesional psoriatic, 
but not normal, epidermal cells potentiate T-cell activa- 
tion.l16 
T-cell cytokines have clear growth regulatory effects 
on keratinocytes. Supernatants from unstimulated 
PBMCs ConA-stimulated PBMCs, and allostimulated 
purified T cells are able to effectively induce or maintain 
keratinocyte proliferation in vitro.“’ The stronger the T 
cells were stimulated, the more their supematants in- 
duced keratinocyte proliferation. Not only mixtures of 
cytokines released by stimulated T cells, but also singIe 
(recombinant) human cytokines may induce or maintain 
their proliferation. 11* Although IFN-y has been shown to 
inhibit the proliferation of keratinocytes in vitro,*19 an 
increased keratinocyte proliferation was measured in 
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viva following its local administration.12o Other cytokines 
with keratinocyte growth-inducing capacities are IL-1 
and IL-6.42*121 Vice versa, keratinocyte-derivedIL-6, IL-7, 
and TNF-(w support T-cell growth.lz2 T cell-derived IFN-y 
induces MHC class II, ICAM-1, and y-IP-10 expression 
on keratinocytes .4*3r1J18 Gamma-IP-10, secreted by acti- 
vated keratinocytes, is a chemoattractant for monocytes 
and activated CD4+ and CD29+ T cells and potentiates 
the adhesion of T cells to endothelial cells.lz3 Phenotypi- 
tally altered “activated” keratinocytes acquire the ability 
to serve as accessory cells for superantigen- or mitogen- 
induced T-cell proliferation. 124 Lymphocyte function-as- 
sociated antigen 1 /ICAM-l interaction is crucial for this 
accessory function. 124 The exact role of the CD28 ligands 
in the accessory cell function of keratinocytes is still un- 
clear.‘“,*= T-cell epidermotropism depends on keratino- 
cyte-derived chemotactic cytokines such as IL-l, IL-8, 
TGF-/?, and the eicosanoid leukotriene B4 (LTB4) and 
keratinocyte adhesion molecules such as E-selectin and 
the B7/BB-1 molecules, which interact with the T-cell 
molecules CLA and CD28, respectively. W&3-l- T cells 
are able to interact with and to penetrate the epidennal 
basement membrane via adhesion to epiligrin, a base- 
ment membrane component.126 
Although the data are not always consistent, it is con- 
ceivable that T cell- keratinocyte interactions cause sev- 
eral alterations in the expression of cytokines and their 
receptors on psoriatic epidermal cells. The regulation of 
IL-1 is clearly abnormal in psoriatic skin; low levels of 
IL-la, elevated levels of a nonfunctional IL-la, and an 
elevated ratio of IL-1 receptor antagonist (IL-l@ to IL-1 
prevail in extracts of lesional psoriatic skin.12~12* Using 
freshly isolated viable cells, we were able to demonstrate 
that lesional psoriatic epidermal cells have an enhanced 
ability to secrete biologically active IL-1pz9 (Debets R. 
Submitted). Epidermal cells from lesion-free skin were 
shown to contain elevated levels of IL-l/?mRNA.3 These 
data indicate that keratinocyte-derived IL-1 may play a 
more important role in the pathogenesis of psoriasis than 
previously assumed. 
Other cytokine abnormalities in psoriatic keratino- 
cytes are increased expression of IL-6, IL-& Gro-a, and 
TGF-a! and overexpression of monocyte chemoattractant 
protein 1 (MCP-1) mRNA.“130-‘33 Cytokine/growth 
factor receptors overexpressed in psoriatic epidermis are 
EGF/TGF+ insulin-like growth factor 1 (IGF-F) and IL- 
4 receptors134J35 (Prens E. Submitted). Decreased expres- 
sion of IL-l receptor has been observed on psoriatic epi- 
dermal cells (Prens E. Submitted). 
In summary, the data presented here clearly illustrate 
that T cell- keratinocyte interactions in psoriasis are re- 
sponsible for enhanced bidirectional cellular activation. 
Minute quantities of cytokines released during these in- 
teractions may trigger a cascade of intercellular cytokine 
signals which induce or boost cutaneous inflammation, or 
both. Therefore, the identification of the primary signal 
and its cellular source in psoriasis remains extremely dif- 
ficult. 
Effects of A&psoriatic Therapies m T Cells 
Potentially effective antipsoriatic drugs may improve 
psoriasis by infIuencing the steps that are important in 
T-cell activation and T-cell t&&king into inflamed tis- 
sue. These steps include mechan&ms such as reducing 
chemokines, downmodulating adheahn molecules on 
endothelial cells and/or keratinocytes, influencing the 
epidermal cytokine milieu, and inhibiting APC function. 
If one or more of these steps are interfered with, it is 
conceivable that also the i&l goal of such a therapy, 
namely, the reduction of keratinocyte proliferation and 
normalization of epidermal architecture, will be 
achieved. It is now known that the most effective anti- 
psoriatic treatment modal&s havemarked immunosup- 
pressive or immunomodulatory effects. Especially the 
observations that cyclosporine A was ef&ctive in clearing 
psoriasis emphasized the roIe of T lymphocytes and cell- 
mediated immune mechanisms in psoriasis.‘36-13e 
Anthralin 
Anthralin (Dithranol), a synthetic substitute for chrysaro- 
bin, acts primarily as an inhibitor of DNA synthesis and 
several cytosolic enzymes and by its clear effects on mito- 
chondria and thus on the cellular respiratory system.139 
Besides the inhibitory effects on DNA synthesis and DNA 
repair in human lymphocytes, little else is known on the 
precise effects of anthralin on lymphocytes. Functional 
studies showed that neutrophil migration is inhibited by 
therapeutically relevant concentr&ms of a&raBn and 
that the allogeneic MECL.R is inhibited, via toxic 
effects on epidermal Langerhans ~ells.‘~ Resolution of 
anthralin-treated psoriatic lesions is accompanied by a 
slight decrease in the number of e@ermal T&Is, but not 
by a decrease in the number of epidermal dendritic 
cells.141 
CycIosporine A 
Cyclosporine A (Cy A), a cyclic polypep&de initially used 
to prevent renal al&raft rejection, by coincidence also 
appeared to improve psoriasis.‘” In subsequent studies, 
CyA appeared to inhibit T-cell activation and the r&ease 
of IL-2.143JcI This property of CyA formed the basis for 
establishing its efficacy in psoria&s and other chronic 
inflammatory diseases in which cell-media&d immune 
reactions were suspected. Analysis of the&era&re allows 
the conclusion that CyA may improve pi&& via two 
different pathways .I46 The first pathway comprises its 
inhibitory effects on cells of the inflammatory infiltrate 
and their soiuble products. The second pathway corn- 
prises its direct antiproliferative ef$ect on keratinocytes, 
which is not discussed further as it is beyond the scope of 
this review. 
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Figure 2. Effect of in vitro preincubafion of lesionaZ epidermal ceZZs (ECs) wifh 
cyclosporin A (CyA) on the autologous MECLR. Lesional ECs were incubated with 2.5 
,ug/mL CyA in RPMl containing 1% human AB serum for 2 hour at 37°C. The cells 
were washed jive times with warm RPM1 complete medium containing 1.5% human AB 
serum. The cultures were pulsed with tritiated thymidine and harvested 8 hours later. 
Bars represent he mean f SEM dpm of quadruplicafe cuhres on fhe day of maximum 
proliferation. The difference between treated (speckled bars) and untreated (solid bars) 
ECs is statistically significant (P < .05, Wilcoxon signed rank sum test). Blank bars 
represent he autologous mixed-lymphocyte reaction of each patient. Reprinted with 
permission from Prens et aL6 - 
Besides inhibition of IL-2, CyA is now also known to 
inhibit transcription of IFN-7, IL-3, IL-4, the IL-8/NAP- 
gene family, and TNF-(x in T lymphocytes.r*3-146 The 
downregulation of ICAM- on endothelial and epidermal 
cells and that of y-IP-10 on keratinocytes following CyA 
treatment are probably secondary to the inhibition of T 
cell-derived cytokines. 147~148 The latter would imply that 
besides the phenotype of keratinocytes, their prolifera- 
tion may also be inhibited via decreased release of 
“growth factors” by T cells. Not only the function, but 
also the number of T lymphocytes in psoriatic lesions is 
reduced by CyA. 14y Immunohistologic studies by differ- 
ent investigators have shown that clinical improvement 
of psoriasis is accompanied by marked reductions in the 
number of activated CD25+ and HLA-DR+ epidermal T 
cells.1*gJ50 The prevailing imbalance of epidennal den- 
dritic cell subsets is restored by a significant increase in 
the number of HLA-DR+/CDla+ cells after CyA ther- 
apy.rsl Although initially debated, there is now agree- 
ment that CyA inhibits the stimulatory capacity of epi- 
dermal APCS.~J~~-‘~~ This inhibition is observed in the 
autologous and allogeneic MECLR following in vitro and 
in vivo CyA treatment, respectively.6,7J54 In the autolo- 
gous MECLR, under carefully defined in vitro conditions, 
preincubation of lesional epidermal cells with CyA sig- 
nificantly inhibited the T-cell response (Fig 2).6 The syn- 
thesis of IL-l, a cytokine essential for the activation of T 
cells during the presentation of antigen, is inhibited in 
APCs by CyA treatment.*55 
Glucocorficosteroids 
Glucocorticosteroids have well-known anti-anflamma- 
tory effects. Their mode of action, particularly their ef- 
fects on T lymphocytes, is still incompletely understood. 
Glucocorticosteroids effectively inhibit DNA synthesis 
via interaction with the glucocorticoid-responsive ele- 
ment and by modulation of Caz+ influx into the cell.‘” 
Synthesis of inflammatory mediators such as arachidonic 
acid metabolites is inhibited via upregulation of lipomo- 
dulin and phospholipase A2.15’ Besides their antiprolifer- 
ative effects on T cells, corticosteroids may also impair 
cytokine production by these cells.ls8 
More detailed data are available on the effects of corti- 
costeroids on APCs. Antigen-presenting capacity and 
also the production of IL-1 are clearly inhibited by corti- 
costeroids.159*160 In vivo treatment of human, mouse, and 
guinea pig skin resulted in “depletion” of epidermal 
APCS.*~*-‘~ This “depletion” consisted in part of a de- 
crease in the number of HLA-DRi- cells and in part of a 
downmodulation of surface membrane markers such as 
CDla and ATPase. Epidermal cells from a normal skin 
area that was treated in vivo with a class IV coriicosteroid 
did not induce antigen-specific T-cell proliferation, 
whereas epidermal cells from an untreated area did so 
effectively.161*162 Treatment of normal skin also resulted 
in a marked decrease in the number of dermal mast 
cells.16” This, together with the capacity of glucocortico- 
steroids to inhibit neutrophil accumulation,16J may be 
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clinically relevant because mast cell degranulation is ob- 
served in emerging prepinpoint psoriatic lesions. Topical 
treatment of psoriatic lesions with a class IV corticosteroid 
resulted in a rapid decrease in the number of activated 
epidermal T cells. 14r The same treatment also resulted in a 
gradual decrease in the number of HLA-DR+ dendritic 
cells, such that even a lower level than in untreated nor- 
mal skin was reached when the lesions resolved.“’ 
Methotrexate 
Methotrexate (MTX) is an antimetabolite that exerts its 
antipsoriatic effects via antagonism of folic acid and inhi- 
bition of thymidylic acid in DNA synthesis. Especially 
cells in S phase, such as the increased pool of epidermal 
cells in S phase in psoriatic lesions, are highly susceptible 
to the antimetabolic effect.‘66~‘67 Again, not much is 
known about the mode of action of MTX on T lympho- 
cytes. The effect of MTX on T lymphocytes in S phase will 
probably be similar, but particularly the weekly cyclic 
dose scheme makes it difficult to predict the in vivo ef- 
fects on lymphocytes; however, a major part of epidermal 
and dermal T lymphocytes in psoriatic lesions are not in S 
phase. Methotrexate, furthermore, inhibits T-cell activa- 
tion by APCs in part via inhibition of IL-l bioacti- 
vity.laJ@ This indicates that probably interference with 
the epidermal compartment, which always contains some 
cycling cells, is a more likely target for MTX. 
Retinoids 
The well-known “normalizing” effects of synthetic reti- 
noids such as etretinate and acitretin on epithelial differ- 
entiation and proliferation are not reviewed here. In this 
section, we discuss the immunomodulatory effects of ret- 
inoids on a variety of hematopoietic cells and nonepithe- 
ha1 tissues. Although the data on the effects of etretinate 
in humans are rather conflicting, an attempt has been 
made to summarize them. The inhibition of neutrophil 
migration was an early event during systemic treatment 
of psoriasis with etretinate. 170*171 Regression of psoriatic 
lesions after treatment with etretinate was accompanied 
by a distinct increase in the number of dermal and epi- 
dermal CDla+ dendritic cells.‘” Inhibition of IFN syn- 
thesis by natural killer cells and blockage of IFN-induced 
upregulation of I-ILA-DR in monocytes and probably ep- 
ithelial cells have also been observed.173*174 Retinoic acid 
may enhance or inhibit T-cell proliferation depending on 
the nature of the stimulus.i” Skin reactions to DNCB 
seemed to be enhanced in patients with psoriasis during 
oral therapy with retinoids. lm Interestingly, retinoic acid 
enhanced epidermal IL-1 production in rats.“’ 
Ultraviolet Therapy 
Although ultraviolet radiation (UVR, UVB, as well as 
PUVA) has clear effects on the human immune system, 
these effects have been studied best in the animal model. 
The effects on the skin immune system include inhibition 
of keratinocyte proliferation, effects on epidermal Lan- 
gerhans cell function, induction of suppressor ce&s, and 
modulation of epidermal cytokine pr~&uct%rn.*~-*~ Epi- 
dermal Langerhans cells were significantly depleted in 
mouse and human skin exposed to UVR.~%S~~ Langer- 
hans cell depletion was accompanied by a decreased abil- 
ity of mouse skin to become sensitized by contact aller- 
gens.*79Jw Similar results have been obtained in humans, 
in whom delayed-type hypersens%ivity responses were 
also markedly inhibited by UVR. UVR causes an increase 
in the synthesis of IL-l and an IL-l antagonist by epider- 
ma1 cells.180-1*2 Cell-mediated reactions may thus be in- 
hibited by antagonism of IL- 1 bioactivity by IL- lra and/ 
or via induction of prostaglandin Q syx&esis in target 
cells by IL-l. Initial results of UV-photopheresis studies 
in psoriasis suggest that T-cell proBferation is directly 
inhibited by photochemotherapy. 
Vitamin D, and Analogs 
1,25Dihydroxyvitamin D3 (calcitriol) and its synthetic 
analog calcipotriol have significant immunomodulatory 
functions.183 Vitamin D,-deficient rats exhibit impaired 
immune responses, mainly because of an impaired APC 
function, that can be restored by supplementation of vi- 
tamin D3.iW The APC function of monocytes and den- 
dritic cells may be inhibited or stimulated by caIci(po)tiol 
depending on their stage of differentiation.*~ The im- 
munomodulatory effects are rather pleiotropic, as they 
are codependent on the cytokine and hormone m&eu, the 
stage of differentiation of the cells involved, and the na- 
ture of eventual ~ostimuli.*~ For example, the obvious 
“normalizing” effect of calci( po)triol on keratinocyte dif- 
ferentiation and proliferation is mediated in part by inhi- 
bition of the production of IL-l and IL-6 in in3ammatory 
cells and enhancement of the production of TGF-/?l and 
p2 by keratinocytes.*86-*88 Besides IL-l and IL-6, vitamin 
D, has also been shown to inhibit the production of lym- 
phokines such as IL-2, TNF-cr, and IFN-y by human 
mononuclear cells.‘s7 The inhibition of IL-2 synthesis by 
T cells indicates that T cells may be a direct target of 
vitamin DB. **’ CD45RO+ memory T ceils seem more sen- 
sitive to the immunosuppressive effects of this drug than 
CD45RAi- T cellszBg The inhibitory effects on T lympho- 
cytes are further potentiated by simultaneously using 
1,25dihydroxyvitamin D3 and CyA.lW 
Calcitriol inhibits IL-8 synthesis in human dermal fi- 
broblasts, keratinocytes, and PBMCs, but not in endothe- 
lial cells.*91 In view of the potent chemotactic properties 
of IL-8 for T lymphocytes and neutroph& this may 
prove to be an important mechanism of action of 
calci(po)triol in psoriasis. 
Conclusions 
Psoriasis may be considered the net outcome of a locally 
ongoing immune inflammation. The earliest signs in 
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emerging lesions are mast cell degranulation and extrav- 
asation of T lymphocytes and monocytes. A wide variety 
of etiologic stimuli such as superantigens, drugs, physical 
(Koebner), and autoimmune stimuli result in a final com- 
mon pathway of inflammation. Proinflammatory media- 
tors released by activated T cells, dendritic APCs, and 
keratinocytes may recruit leukocytes and initiate skin in- 
flammation via interactive signaling between resident 
and nonresident skin cells and ECM components. The 
type and the mixture of chemotactic and cell-activating 
cytokines during the early phases of inflammation dictate 
the net migratory behavior of the inflammatory cells. 
Selectin and integrin interactions in the dermis, the 
ECM, and the epidermis are crucial to the development 
and regulation of inflammation in psoriasis. The se- 
quence of events discussed above represents a finely bal- 
anced functional network of interactions between cellular 
constituents of the skin immune system, their soluble 
products, and the ECM. Imbalances or genetically deter- 
mined inabilities to produce or tendencies for overpro- 
duction of certain molecules of this interactive system 
form the basis of skin diseases such as psoriasis. One 
should, however, bear in mind that the cascade of T cell - 
ECM-keratinocyte interaction-derived proinflammatory 
cytokines operative in psoriasis under normal conditions 
(eg, would healing) has beneficial effects for the host. 
The majority of the antipsoriatic therapies, apart from 
their effects on keratinocyte proliferation and differentia- 
tion, also interfere in crucial processes such as antigen 
presentation to T cells, T-cell activation/proliferation, 
and T-cell trafficking into inflamed tissue in psoriasis. 
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